These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 21343372)

  • 21. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer.
    van der Horst G; van den Hoogen C; Buijs JT; Cheung H; Bloys H; Pelger RC; Lorenzon G; Heckmann B; Feyen J; Pujuguet P; Blanque R; Clément-Lacroix P; van der Pluijm G
    Neoplasia; 2011 Jun; 13(6):516-25. PubMed ID: 21677875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
    Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
    Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Inhibition of bladder cancer cell growth and angiogenesis by co-blockage of vascular endothelial growth factor and its receptor KDR].
    Chen XL; Liu LC; Xu ZG; Li Z; Li RW; Gao RJ; Wang S; Zhang M; Guo H
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):578-82. PubMed ID: 19102933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.
    Yang J; Fizazi K; Peleg S; Sikes CR; Raymond AK; Jamal N; Hu M; Olive M; Martinez LA; Wood CG; Logothetis CJ; Karsenty G; Navone NM
    Cancer Res; 2001 Jul; 61(14):5652-9. PubMed ID: 11454720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
    Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
    Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice.
    Gu JW; Young E; Busby B; Covington J; Johnson JW
    Cancer Biol Ther; 2009 Mar; 8(6):514-21. PubMed ID: 19242105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.
    Morrissey C; Lai JS; Brown LG; Wang YC; Roudier MP; Coleman IM; Gulati R; Vakar-Lopez F; True LD; Corey E; Nelson PS; Vessella RL
    Prostate; 2010 Mar; 70(4):412-24. PubMed ID: 19866469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
    Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
    J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor agent cabozantinib decreases RANKL expression in osteoblastic cells and inhibits osteoclastogenesis and PTHrP-stimulated bone resorption.
    Stern PH; Alvares K
    J Cell Biochem; 2014 Nov; 115(11):2033-8. PubMed ID: 25042887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
    Xiang Y; Li Q; Huang D; Tang X; Wang L; Shi Y; Zhang W; Yang T; Xiao C; Wang J
    Exp Biol Med (Maywood); 2015 Feb; 240(2):160-8. PubMed ID: 25125500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.
    Parameswaran R; Yu M; Lyu MA; Lim M; Rosenblum MG; Groffen J; Heisterkamp N
    Leukemia; 2012 Aug; 26(8):1786-96. PubMed ID: 22373785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteostatin improves the osteogenic activity of fibroblast growth factor-2 immobilized in Si-doped hydroxyapatite in osteoblastic cells.
    Lozano D; Feito MJ; Portal-Núñez S; Lozano RM; Matesanz MC; Serrano MC; Vallet-Regí M; Portolés MT; Esbrit P
    Acta Biomater; 2012 Jul; 8(7):2770-7. PubMed ID: 22487933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel.
    Cho EJ; Yang J; Mohamedali KA; Lim EK; Kim EJ; Farhangfar CJ; Suh JS; Haam S; Rosenblum MG; Huh YM
    Invest Radiol; 2011 Jul; 46(7):441-9. PubMed ID: 21512397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
    Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
    Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro.
    Cao Z; Lin W; Huang Z; Chen X; Zhao J; Zheng L; Ye H; Liu Z; Liao L; Du J
    Oncol Rep; 2013 Mar; 29(3):1080-6. PubMed ID: 23254951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.